Literature DB >> 7645925

Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract.

N H Chow1, S M Huang, S H Chan, L R Mo, M H Hwang, W C Su.   

Abstract

There were few, but conflicting, reports dealing with the clinical significance of c-erbB-2 in biliary tract cancer. We evaluated the expression of c-erbB-2 in normal epithelium of bile ducts (n = 46), gallbladder cancer (n = 11), carcinoma of the ampulla of Vater (n = 18), and intrahepatic cholangiocarcinoma (CC) (n = 18). c-erbB-2 protein is present in 63% (29/46) of surface epithelium in large and septal bile ducts, but not in peripheral small ducts. Overexpression of the gene product was found in 27.8% (5/18) of intrahepatic CC, 27.8% (5/18) of carcinoma of the ampulla of Vater, and 63.6% (7/11) of gallbladder cancer. But, there was no c-erbB-2 overexpression in the hyperplasia or atypical hyperplastic bile duct epithelium (p = 0.002). In terms of prognostic implication, expression of c-erbB-2 did not correlate to the histopathological grade (p = 0.60) and tumor stage (p = 0.63). The results indicate that c-erbB-2 protein may play some roles in physiology of normal bile ducts. Overexpression of the gene product occurs in one forth to about two thirds of carcinoma of biliary tract, and may be used as phenotypic marker for neoplastic transformation. However, the gene product may not be important in the aggressive behavior of tumor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7645925

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

1.  Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

Authors:  Siobhan C McKay; Kristian Unger; Stephanos Pericleous; Gordon Stamp; Gerry Thomas; Robert R Hutchins; Duncan R C Spalding
Journal:  HPB (Oxford)       Date:  2011-03-10       Impact factor: 3.647

2.  A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status.

Authors:  Hiroshi Yoshida; Kazuaki Shimada; Tomoo Kosuge; Nobuyoshi Hiraoka
Journal:  Virchows Arch       Date:  2016-01-13       Impact factor: 4.064

3.  Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders.

Authors:  W C Su; S C Shiesh; H S Liu; C Y Chen; N H Chow; X Z Lin
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

4.  HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma.

Authors:  Hee Jin Lee; Joon-Yong Chung; Stephen M Hewitt; Eunsil Yu; Seung-Mo Hong
Journal:  Virchows Arch       Date:  2012-10-02       Impact factor: 4.064

5.  FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma.

Authors:  J Settakorn; N Kaewpila; G F Burns; A S-Y Leong
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

6.  EGFR and HER2 expression in advanced biliary tract cancer.

Authors:  Jan Harder; Oliver Waiz; Florian Otto; Michael Geissler; Manfred Olschewski; Brigitte Weinhold; Hubert E Blum; Annette Schmitt-Graeff; Oliver G Opitz
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

7.  Characterization and growth regulation of a rat intrahepatic bile duct epithelial cell line under hormonally defined, serum-free conditions.

Authors:  P C de Groen; B Vroman; K Laakso; N F LaRusso
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-10       Impact factor: 2.416

Review 8.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

9.  HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer.

Authors:  Toru Kawamoto; Savitri Krishnamurthy; Emily Tarco; Smita Trivedi; Ignacio I Wistuba; Donghui Li; Ivan Roa; Juan C Roa; Melanie B Thomas
Journal:  Gastrointest Cancer Res       Date:  2007-11

10.  Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma (GBC).

Authors:  Chhanda Das; Madhumita Mukhopadhyay; Srijana Subba; Ashis Kumar Saha; Biswanath Mukhopadhyay
Journal:  J Lab Physicians       Date:  2021-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.